Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey Acquires 5,000 Shares

Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey bought 5,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the purchase, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Biohaven Stock Performance

BHVN stock opened at $45.01 on Wednesday. The business has a 50-day moving average price of $38.65 and a 200 day moving average price of $40.65. Biohaven Ltd. has a 1-year low of $17.17 and a 1-year high of $62.21.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing the consensus estimate of ($1.72) by ($1.92). On average, equities analysts anticipate that Biohaven Ltd. will post -8.92 EPS for the current year.

Hedge Funds Weigh In On Biohaven

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Biohaven by 280.5% in the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after purchasing an additional 4,650,702 shares in the last quarter. Stifel Financial Corp boosted its position in Biohaven by 7.9% in the 4th quarter. Stifel Financial Corp now owns 6,225,811 shares of the company’s stock worth $266,465,000 after purchasing an additional 456,062 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Biohaven by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock worth $183,050,000 after purchasing an additional 212,699 shares in the last quarter. Point72 Asset Management L.P. boosted its position in Biohaven by 142.2% in the 4th quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock worth $106,297,000 after purchasing an additional 1,458,072 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its position in Biohaven by 181.4% in the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after purchasing an additional 1,449,000 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

BHVN has been the topic of several research reports. Royal Bank of Canada boosted their price objective on shares of Biohaven from $59.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday. Jefferies Financial Group initiated coverage on shares of Biohaven in a research note on Monday, September 16th. They set a “buy” rating and a $57.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday. Sanford C. Bernstein lifted their target price on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday. Thirteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average target price of $60.92.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.